AIM ImmunoTech CEO buys 24,000 shares at $0.208
AIM ImmunoTech Inc. (AIM) reported that CEO and President Thomas K. Equels purchased 24,000 shares of common stock in a open market or private transaction on September 17, 2026, at $0.208 per share, bringing his directly held position to 126,822 shares.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
AIM ImmunoTech Inc. (AIM) reported that CEO and President Thomas K. Equels purchased 24,000 shares of common stock in a open market or private transaction on September 17, 2026, at $0.208 per share, bringing his directly held position to 126,822 shares.
No Rule 10b5-1 trading plan is reported for this transaction.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 24,000 | $0.208 | $5K |
Key Figures
Key Terms
Rule 10b5-1 trading plan regulatory
open market or private transaction market
Form 4 regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did AIM ImmunoTech (AIM) report for Thomas K. Equels?
Was the AIM ImmunoTech (AIM) insider trade made under a Rule 10b5-1 plan?
Is the AIM ImmunoTech (AIM) CEO’s ownership direct or indirect after this transaction?
AI-generated analysis. How Rhea-AI works. Not financial advice.